Related Experiment Video
Updated: Jul 4, 2026
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells
S Kumar1, S L Brown, A Kolozsvary
1Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA. skumar4@hfhs.org
Abstract:
Viral vector mediated suicide gene therapy (SGT) involving thymidine kinase (TK) or cytosine deaminase (CD) have considerable promise in the treatment of malignant brain tumors. An unresolved issue is to what extent tumor hypoxia influences the outcome of SGT since brain tumors characterized by regions of hypoxia have potentially reduced cellular metabolism and SGT's cytotoxicity is manifest through cellular metabolism. We studied in vitro and in vivo, the effect of hypoxia on the cytotoxicity of SGT in rat 9L glioma cells. Neither acute nor chronic hypoxia affected the cell killing of SGT by TK or CD. In vivo confirmation that SGT efficacy was not adversely affected by tumor hypoxia using the hypoxic cell marker pimonidazole was shown by the absence of a change in tumor hypoxia by SGT. These studies support the use of SGT utilizing either TK or CD gene strategies even when tumors are characterized by a hypoxic microenvironment.
Insights
Suicide gene therapy (SGT) using thymidine kinase (TK) or cytosine deaminase (CD) effectively treats brain tumors, even in hypoxic conditions. Hypoxia does not reduce SGT
Area of Science:
- Oncology
- Gene Therapy
- Cancer Research
Background:
- Malignant brain tumors are a significant challenge in oncology.
- Viral vector-mediated suicide gene therapy (SGT) shows promise for brain tumor treatment.
- Tumor hypoxia, a common feature of solid tumors, may impact SGT efficacy due to reduced cellular metabolism.
Purpose of the Study:
- To investigate the influence of tumor hypoxia on the efficacy of SGT.
- To evaluate the effect of hypoxia on SGT utilizing thymidine kinase (TK) or cytosine deaminase (CD) gene strategies in rat 9L glioma cells.
Main Methods:
- In vitro and in vivo studies were conducted using rat 9L glioma cells.
- The cytotoxicity of SGT under both acute and chronic hypoxic conditions was assessed.
- In vivo experiments utilized the hypoxic cell marker pimonidazole to confirm tumor hypoxia levels.
Main Results:
- Neither acute nor chronic hypoxia significantly affected the cell-killing efficacy of SGT mediated by TK or CD.
- In vivo studies confirmed that SGT did not adversely impact tumor hypoxia levels.
- Pimonidazole staining showed no change in tumor hypoxia after SGT treatment.
Conclusions:
- Tumor hypoxia does not diminish the effectiveness of viral vector-mediated SGT.
- SGT strategies employing TK or CD are viable treatment options for malignant brain tumors, irrespective of hypoxic microenvironments.
- These findings support the clinical application of SGT in brain tumors with varying degrees of hypoxia.
